HIV-1 Infection of Long-Lived Hematopoietic Precursors In Vitro and In Vivo

Cells. 2022 Sep 23;11(19):2968. doi: 10.3390/cells11192968.

Abstract

Latent reservoirs in human-immunodeficiency-virus-1 (HIV-1)-infected individuals represent a major obstacle in finding a cure for HIV-1. Hematopoietic stem and progenitor cells (HSPCs) have been described as potential HIV-1 targets, but their roles as HIV-1 reservoirs remain controversial. Here we provide additional evidence for the susceptibility of several distinct HSPC subpopulations to HIV-1 infection in vitro and in vivo. In vitro infection experiments of HSPCs were performed with different HIV-1 Env-pseudotyped lentiviral particles and with replication-competent HIV-1. Low-level infection/transduction of HSPCs, including hematopoietic stem cells (HSCs) and multipotent progenitors (MPP), was observed, preferentially via CXCR4, but also via CCR5-mediated entry. Multi-lineage colony formation in methylcellulose assays and repetitive replating of transduced cells provided functional proof of susceptibility of primitive HSPCs to HIV-1 infection. Further, the access to bone marrow samples from HIV-positive individuals facilitated the detection of HIV-1 gag cDNA copies in CD34+ cells from eight (out of eleven) individuals, with at least six of them infected with CCR5-tropic HIV-1 strains. In summary, our data confirm that primitive HSPC subpopulations are susceptible to CXCR4- and CCR5-mediated HIV-1 infection in vitro and in vivo, which qualifies these cells to contribute to the HIV-1 reservoir in patients.

Keywords: CXCR4 and CCR5 tropism; HIV-1 infection; colony formation; hematopoietic stem and progenitor cells (HSPCs); hematopoietic stem cells (HSC); in vitro and in vivo; multipotent progenitor cells (MPP); proviral DNA; replating assays; viral reservoir.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • DNA, Complementary
  • HIV Infections*
  • HIV-1* / physiology
  • Hematopoietic Stem Cells
  • Humans

Substances

  • DNA, Complementary

Grants and funding

This research was funded in part by the Federal Ministry for Education and Research (01ES0710 to U.D.), the Dr. Bodo Sponholz Foundation (U.D.), a postdoctoral fellowship from the Georg-Speyer-Haus (R.D.), and the Merck Investigator Studies Program (MISP), grant #57483 (R.D.). M.A.R. was supported by the German Research Foundation (SFB834 Z1 project), the Hessisches Ministerium für Wissenschaft und Kunst (III L 5-519/03/03.001-[0015]), the Deutsche Jose Carreras Leukämie-Stiftung (Grant 11R/2020), and the Wilhelm Sander-Stiftung (Grant 2018.116.1). The Georg-Speyer-Haus is supported by the Federal Ministry of Health and the Ministry for Higher Education, Science and the Arts from the state of Hessen, Germany.